In a systemic sclerosis animal model, the PDE inhibitor nerandomilast has been shown to alleviate skin and lung fibrosis through the inhibition of PDE and consequent dampening of the TGF-β pathway [213]. This evidence concerns the gene TGFB1 and systemic sclerosis.